Company profile
Atai Beckley Inc.
NASDAQ: ATAI · Healthcare · Biotechnology
#966 of 1,418 Healthcare companies by revenue38th-percentile growth
EA Score
——FH —DQ 31GM —SS 57
v0.1 · 25/100 weight · pillars only
↑ market scale, Altman-Z · ↓ net margin, operating margin
Methodology →Revenue TTM
$3.5M
Rev growth YoY (TTM)
+87.2%
Net income (FY)
-$149.3M
Employees
99
as of 2026-08-09
Market cap
$2.7B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$308.0k$308.0k2024
Net income-$149.3M-$149.3M2024
Operating income-$102.7M-$102.7M2024
Total assets$159.4M$159.4M2024
Liabilities$42.8M$42.8M2024
Equity$116.3M$116.3M2024
Revenue trend
FY2021 – FY2024 · USD
FY21
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2024
By product
Research And Development Services100%
By geography
Not disclosed.
The read
What is Atai Beckley Inc.’s revenue?
Atai Beckley Inc. booked $308.0k in FY2024 revenue, contracting 1.9% year over year — slower than 62% of Healthcare companies we track, at a -48464.0% net margin.
Peers · Healthcare
Vyome Holdings, Inc.33DInteractive Health Network——Medixall Group, Inc.——Kane Biotech Inc.24DCannabis Bioscience International Holdings, Inc.18DNexalin Technology, Inc.34DNeighbors
New York →Key facts
CEOSrinivas G. Rao
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York, NY
ExchangeNASDAQ: ATAI
Employees99
IPO date2021-06-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.